Biotechnology company Adolor Corp. said yesterday that it bought exclusive worldwide rights to Eli Lilly and Co.’s OpRA
III drug candidate, which has a range of potential uses.
Exton, Pa.-based Adolor will pay $2 million upfront to
Indianapolis-based Eli Lilly, along with future royalties and milestone payments potentially worth $70 million.
said it initially intends to develop the drug candidate as a potential opioid bowel-dysfunction treatment and will start clinical
trials in early 2010. The condition normally refers to chronically constipated patients taking opioid pain drugs.